Feuerstein comments hit Ampio in early trading

Ampio Pharmaceuticals (AMPE) is trading 6.6% lower premarket.

Likely behind the move is TheStreet's Adam Feuerstein who, in a response to an article by SA contributor Brian Wilson, says the company "slipped in" new disclosures regarding Optina in the prospectus for its most recent financing.

According to Feuerstein, the company's disclosure that "the FDA has previously indicated that a Phase 3 trial may be necessary following the current trial" is quite a change of pace from the language present in AMPE's March 10-Q.

"The FDA has never approved a drug for DME based on a 12-week clinical trial," Feuerstein says.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs